Feasibility study on measuring selected proteins in malignant melanoma tissue by SRM quantification

Area of Science:

• Proteomics
• Mass Spectrometry
• Cancer Biomarkers

Background:

• Malignant melanoma (MM) lacks clinically validated molecular biomarkers for staging or therapy response assessment.
• Accurate protein quantification is crucial for identifying reliable diagnostic and prognostic markers in cancer.

Purpose of the Study:

• To develop and validate targeted selected reaction monitoring (SRM) assays for identifying protein biomarkers in metastatic melanoma.
• To assess the feasibility of using SRM for quantifying candidate proteins in patient tissue samples.

Main Methods:

• Development of targeted SRM assays using a TSQ Vantage triple quadrupole mass spectrometer.
• Quantification of nine selected proteins (C3, CD3E, dermatopontin, MCM4, PMEL, S100A8, S100A13, transgelin-2, S100B) in metastatic melanoma tissue lysates.
• Validation of assay accuracy using internal standards and analysis of patient samples from a biobank.

Main Results:

• The SRM assay demonstrated high accuracy with relative standard deviations from 6% to 15%.
• All nine target proteins were successfully identified and quantified in metastatic melanoma tissue samples.
• S100B protein, a known MM identifier, was detected in 9 out of 10 patient samples.

Conclusions:

• Targeted SRM assays are feasible for accurate protein biomarker quantification in malignant melanoma.
• Preliminary data suggest heterogeneity in protein biomarker expression among MM patients.
• This assay format holds promise for advancing MM diagnosis and monitoring therapeutic response.